Literature DB >> 1859010

Absorption and bioavailability of oral transmucosal fentanyl citrate.

J B Streisand1, J R Varvel, D R Stanski, L Le Maire, M A Ashburn, B I Hague, S D Tarver, T H Stanley.   

Abstract

Oral transmucosal fentanyl citrate (OTFC) is a novel, noninvasive dosage form of fentanyl used to provide children and adults with sedation, anxiolysis, and analgesia. In order to determine the bioavailability and absorption of fentanyl from OTFC, 12 volunteers were given intravenous fentanyl citrate or OTFC 15 micrograms/kg on each of two occasions. On a third occasion, the authors assessed oral administration (gastrointestinal absorption) by giving eight of the same volunteers the same dose of a solution of fentanyl citrate to swallow. In each study, arterial blood samples were taken over 24 h for analysis of plasma fentanyl. After intravenous (iv) administration of fentanyl, clearance (mean +/- standard deviation) was 0.67 +/- 0.15 l/min; volume of distribution at steady state was 287 +/- 79 l; and the terminal elimination half-life was 425 +/- 102 min. Peak plasma concentrations of fentanyl were higher (3.0 +/- 1.0 vs. 1.6 +/- 0.6 ng/ml, P = 0.01) and occurred sooner (22 +/- 2.5 vs. 101 +/- 48.8 min, P = 0.003) after OTFC than after oral solution administration. Plasma concentrations of fentanyl after OTFC decreased rapidly, to less than 1.0 ng/ml within 75-135 min after the beginning of administration. Peak absorption rate was greater (11.1 +/- 4.3 vs. 3.6 +/- 2.1 micrograms/min, P = 0.004) and occurred much sooner after OTFC than after oral solution administration (19 +/- 2.6 vs. 87.5 +/- 38.1 min, P = 0.001). Systemic bioavailability was greater after OTFC administration than after the oral solution (0.52 +/- 0.1 vs. 0.32 +/- 0.1, P = 0.01).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1859010     DOI: 10.1097/00000542-199108000-00009

Source DB:  PubMed          Journal:  Anesthesiology        ISSN: 0003-3022            Impact factor:   7.892


  39 in total

Review 1.  Breakthrough pain in cancer patients: new therapeutic approaches to an old challenge.

Authors:  S K Reddy; P Nguyen
Journal:  Curr Rev Pain       Date:  2000

2.  Fatal outcome in a child after ingestion of a transdermal fentanyl patch.

Authors:  Jörg Teske; Jens-Peter Weller; Klaus Larsch; Hans Dieter Tröger; Matthias Karst
Journal:  Int J Legal Med       Date:  2006-11-18       Impact factor: 2.686

Review 3.  [Cancer breakthrough pain. Indications for rapidly effective opioids].

Authors:  J Kessler; H J Bardenheuer
Journal:  Anaesthesist       Date:  2011-07       Impact factor: 1.041

4.  [Safety and efficacy of oral trans-mucosal fentanyl citrate in the long-term treatment of breakthrough pain in oncology patients: the ECODIR study].

Authors:  Vicente Valentín Maganto; Carlos Camps Herrero; Joan Carulla Torrent; Javier Cassinello Espinosa; Javier Dorta Delgado; Carlos Jara Sánchez; José Andrés Moreno Nogueira
Journal:  Clin Transl Oncol       Date:  2005-06       Impact factor: 3.405

Review 5.  Strategies for the treatment of cancer pain in the new millennium.

Authors:  C Ripamonti; E D Dickerson
Journal:  Drugs       Date:  2001       Impact factor: 9.546

6.  Development of a GC-MS assay for the determination of fentanyl pharmacokinetics in rabbit plasma after sublingual spray delivery.

Authors:  Ahmad H Malkawi; Abeer M Al-Ghananeem; Peter A Crooks
Journal:  AAPS J       Date:  2008-05-06       Impact factor: 4.009

7.  Comparative absorption kinetics of intramuscular midazolam and diazepam.

Authors:  O R Hung; J B Dyck; J Varvel; S L Shafer; D R Stanski
Journal:  Can J Anaesth       Date:  1996-05       Impact factor: 5.063

Review 8.  Oral mucosal drug delivery: clinical pharmacokinetics and therapeutic applications.

Authors:  Hao Zhang; Jie Zhang; James B Streisand
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

Review 9.  Management of breakthrough pain in patients with cancer.

Authors:  Leeroy William; Rod Macleod
Journal:  Drugs       Date:  2008       Impact factor: 9.546

Review 10.  Oral transmucosal fentanyl citrate in cancer pain management: a practical application of nanotechnology.

Authors:  Kyriaki Mystakidou; Eleni Tsilika; Marinos Tsiatas; Lambros Vlahos
Journal:  Int J Nanomedicine       Date:  2007
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.